Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure, Circulation, vol.124, pp.1059-1069, 2011. ,
Epoxyeicosatrienoic acids contribute with altered NO and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension, Circulation, vol.125, pp.1266-1275, 2012. ,
Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?, Pharmacol Ther, vol.131, pp.1-17, 2011. ,
Diabetic cardiomyopathy, causes and effects, Rev Endocr Metab Disord, vol.11, pp.31-39, 2010. ,
Expression and regulation of soluble epoxide hydrolase in adipose tissue, Obesity (Silver Spring), vol.18, pp.489-498, 2010. ,
Inhibition of soluble epoxide hydrolase reduces food intake and increases metabolic rate in obese mice, Nutr Metab Cardiovasc Dis, vol.22, pp.598-604, 2012. ,
Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome, Mediators Inflamm, p.136584, 2013. ,
Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension, J Hypertens, vol.29, pp.1128-1135, 2011. ,
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats, Am J Physiol Heart Circ Physiol, vol.303, pp.853-862, 2012. ,
Orally bioavailable potent soluble epoxide hydrolase inhibitors, J Med Chem, vol.50, pp.3825-3840, 2007. ,
Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats, Exp Diabetes Res, p.758614, 2012. ,
, Cardiovascular Consequences of Obesity and Type 2 Diabetes: Soluble
Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture, Diabetes Care, vol.33, pp.442-449, 2008. ,
Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice, PLoS One, vol.7, p.39165, 2012. ,
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis, J Pharmacol Exp Ther, vol.334, pp.430-438, 2010. ,
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance, Proc Natl Acad Sci, vol.108, pp.9038-9043, 2011. ,
Cardiacspecific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice, Endocrinology, vol.154, pp.2843-2856, 2013. ,
Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies, Lancet, vol.371, pp.1800-1809, 2008. ,
Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure, J Mol Cell Cardiol, vol.52, pp.660-666, 2012. ,
Epoxyeicosatrienoic acidinduced relaxation is impaired in insulin resistance, Am J Physiol Heart Circ Physiol, vol.281, pp.1524-1531, 2001. ,
Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health, Annu Rev Pharmacol Toxicol, vol.53, pp.37-58, 2013. ,
Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM, Diabetes, vol.46, pp.1010-1016, 1997. ,
Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications, Rev Endocr Metab Disord, vol.11, pp.61-74, 2010. ,
Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes, Am J Cardiovasc Drugs, vol.12, pp.7-22, 2012. ,
Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice, Diabetes, vol.59, pp.997-1005, 2010. ,
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension, Eur J Pharmacol, vol.654, pp.68-74, 2011. ,
Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats, Am J Physiol Regul Integr Comp Physiol, vol.288, pp.188-196, 2005. ,
, Cardiovascular Consequences of Obesity and Type 2 Diabetes: Soluble
, A: mean values and representative recordings), inhibitory effect of N -nitro--arginine ( -NA), N-methylsulfonyl-6-(2-propargyloxyphenyl)-hexanamide (MSPPOH), -NA + MSPPOH, and apamin + TRAM34 on the relaxations to 3 × 10 M acetylcholine (B), endothelium-independent relaxations to sodium nitroprusside (C), and relaxations to NS309 (D) and NS1619 (E), at W16 in control mice, Coronary endothelium-dependent relaxations to acetylcholine (ACh) after vessel contraction with 10 M serotonin (HT) under basal conditions
,
, ?P < 0.05, HFD + t-AUCB vs
, ?P < 0.05, HFD + t-AUCB vs
, §P < 0.05, -NA vs
, Cardiovascular Consequences of Obesity and Type 2 Diabetes: Soluble
, Western-blot analysis of left descending coronary artery protein expressions of endothelial nitric oxide synthase (eNOS), soluble epoxide hydrolase (sEH), and large-conductance calcium-activated potassium (BK ) channels, normalized to smooth muscle actin at W16 in control mice (n = 6-8)
, Cardiovascular Consequences of Obesity and Type 2 Diabetes: Soluble